PURPOSE The risk of immune checkpoint inhibitor therapy–related GI adverse events in
patients with cancer and inflammatory bowel disease (IBD) has not been well described. We …

Background Immune checkpoint inhibitors may variably impact patients with pre‐existing
autoimmune diseases. Aims To evaluate the risks and outcomes of adverse events in …

Aim: We performed a meta-analysis of the risk of selected gastrointestinal toxicities
associated with immune checkpoint inhibitors. Patients & methods: Eligible studies included …

Background Immune checkpoint inhibitors (ICI) have demonstrated remarkable efficacy as
cancer therapeutics, however, their use remains limited due to the development of immune …

Abstract Background Immune checkpoint inhibitors (ICIs) have improved cancer outcomes.
However, immune-related adverse effects are common. The aim was to investigate the …

Background Immune checkpoint inhibitors (ICPI) are efficacious treatments for advanced
malignancies but can result in immune mediated diarrhea and colitis (IDC). Currently, the …

PURPOSE Immune checkpoint inhibitor (ICI) therapy often is suspended because of
immune-mediated diarrhea and colitis (IMDC). We examined the rate of and risk factors for …

Background Immune checkpoint inhibitors are successfully introduced as anticancer
treatment. However, they may induce severe immune-related adverse events (irAEs). One of …

Immune checkpoint inhibitors (ICIs) have improved the treatment of several cancers. These
drugs increase T-cell activity and the antitumor immune response but also have immune …

Immunotherapy with checkpoint inhibitors has revolutionized cancer therapy and is now the
standard treatment for several different types of cancer, supported by favorable outcomes …